
Jonathan W. Friedberg, MD
Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA
Jonathan W. Friedberg is Professor of Medicine, Chief, Hematology/Oncology Division and Director of the Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY. He is a member of the lymphoma committee in the Southwest Oncology Group, and serves as principal investigator on many local and national lymphoma treatment protocols for both Hodgkin lymphoma and non-Hodgkin’s lymphoma. He is an attending physician at Strong Memorial Hospital, on the hematological malignancies and blood and marrow transplant service.
Dr. Friedberg received his medical degree from Harvard Medical School. His postgraduate training included an internship and residency at Massachusetts General Hospital. He also completed a medical oncology and hematology fellowship at Dana-Farber/Partners Cancer Care in Boston. Dr. Friedberg also has an M.M.Sc. degree from Harvard Medical School in clinical investigation, upon completion of a rigorous training program in drug development, clinical trial design and analysis. He is board certified in Internal Medicine and holds subspecialty certification in Hematology.
Dr. Friedberg’s research interests focus on development of novel therapies for patients with lymphoma. For his work on B-cell receptor signaling inhibition, he was designated a Scholar in Clinical Research of the Leukemia & Lymphoma Society. He also plays a leadership role in the University of Rochester SPORE in lymphoma grant, directing the clinical trials core, and co-leading a project on novel targeted combination therapy for relapsed lymphoma. He is medical director of the NCCN lymphoma outcomes database, and on the Scientific Advisory Board of the National LymphoCare Study.
Dr. Friedberg is a member of the Education Committee for the American Society of Hematology, and on the Planning Committee of the International Conference on Malignant Lymphoma (Lugano). He serves on multiple Editorial Boards, and was recently named Associated Editor of the Journal of Clinical Oncology.
Editorial Board
Terms of Appointment: September 2018 - October 2020; September 2020 - October 2022; October 2022 - September 2024